Heterocycle Synthesis Based on Allylic Alcohol Transposition Using Traceless Trapping Groups
作者:Youwei Xie、Paul E. Floreancig
DOI:10.1002/anie.201402010
日期:2014.5.5
Allylic alcohols undergo transposition reactions in the presence of Re2O7 whereby the equilibrium can be dictated by trapping one isomer with a pendent electrophile. Additional ionization can occur when the trapping group is an aldehyde or ketone, thus leading to cyclic oxocarbenium ion formation. Terminating the process through bimolecular nucleophilic addition into the intermediate provides a versatile
烯丙醇在Re 2 O 7的存在下进行转座反应,从而可以通过用一种亲电亲和剂捕获一种异构体来控制平衡。当捕获基团是醛或酮时,可能会发生其他电离,从而导致形成环氧碳鎓离子。通过将双分子亲核加成至中间物来终止该过程,为合成各种含氧杂环化合物提供了一种通用的方法。了解序列中各步骤的相对速率会导致设计反应,从而创建多个具有良好至极佳控制水平的立体中心。
Crisan, Annales de Chimie (Cachan, France), 1956, vol. <13>1, p. 436,459
作者:Crisan
DOI:——
日期:——
——
作者:E. A. Matyushenkov、D. G. Churikov、N. A. Sokolov、O. G. Kulinkovich
DOI:10.1023/a:1026047515568
日期:——
Reaction of 2-vinyltetrahydrofuran and 2-vinyltetrahydropyran with ethylmagnesium bromude in the presence ot titanium(IV) isopropoxide afforded in moderate selectivity trans-4-octen-1-ol and trans-5-nonen-1-ol respectively. Best yields and high stereochemical purity of products were obtained in ethylation under these conditions of 2-(cis-1-propenyl)tetrahydrofuran, 2-(cis-1-proprnyl)- and 2- (trans-1-propenyl) tetrahydropyran. It is assumed that the key organometallic intermediate formed was diisopropoxy-titanacycloprpopane, and direction of its addition to the doubel bond governed the streochemistry of the resulting product. The obtained trans-4-octen-1-ol and trans-7-methyl-5-nonen-1-ol were applied as initial products in the synthesis of sex pheromones of lesser plum worm (Grafolita funebrana) and tea leaf roller moth (Adoxophyes sp).
Ficini, Bulletin de la Societe Chimique de France, 1956, p. 119,122
作者:Ficini
DOI:——
日期:——
PROTEIN SECRETION INHIBITORS
申请人:KEZAR LIFE SCIENCES
公开号:US20220153732A1
公开(公告)日:2022-05-19
Provided herein are secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same, wherein the compound has a structure of Formula (I), (II), or (III).